Recent Research on Immunotherapy in Ovarian Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (25 September 2024) | Viewed by 20630
Special Issue Editor
Special Issue Information
Dear Colleagues,
Ovarian cancer remains one of the most lethal of gynaecological malignancies, characterised in most patients by the rapid acquisition of chemo-resistance. Substantial molecular heterogeneity at diagnosis further complicates treatment choices and efficacy. Accordingly, more than 80% of ovarian cancer patients experience recurrent disease and more than 50% of these patients die from the disease in less than five years post-diagnosis. Therefore, there is an urgent need for new treatments.
Immunotherapy has shown potential for ovarian cancer and several clinical trials testing new treatments are currently underway, including immune checkpoint inhibitors, cancer vaccines, oncolytic viruses, bispecific T-cell engagers and engineered cell therapies. Despite this expanding arsenal, there still are no approved immunotherapies for ovarian cancer. In this Special Issue of Cancers, experts in the field will review the current knowledge about ovarian cancer immunotherapy and the barriers that remain for clinical implementation, as well as new research aimed towards more effectively applying immunotherapy to the treatment of ovarian cancer.
Dr. John Stagg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- immunotherapy
- immune checkpoint
- CAR T cells
- cancer vaccine
- BITE
- oncolytic virus
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
